This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Geron Stem Cell Trial Risky, Doctors Warn

Geron's (GERN - Get Report) upcoming and widely publicized stem cell trial involving patients with spinal cord injuries was criticized as risky and clinically dubious because the entire rationale for the study is "based on a single experiment in eight rats."

The negative view of Geron's research effort came from a spinal surgeon and stem cell researcher during a conference call for institutional investors held Monday by Summer Street Research Partners, an independent health care research firm.

A recording of the conference call was obtained by TheStreet.com, which chose not to disclose the doctor's name out of privacy concerns since the call was not intended for public dissemination. At the beginning of the call, the doctor said he had no financial ties to Geron, nor did he own or short Geron stock.

In January, the Food and Drug Administration granted Geron permission to launch a small safety study of its human embryonic stem cell-derived therapy in patients paralyzed from the waist down due to severe spinal cord injury. Geron and other stem cell advocates hailed the study's start as a landmark achievement in the nascent field of regenerative medicine.

But investors have had a less enthusiastic reaction to the news. The price of Geron shares rose from $5 to more than $8 in the days immediately after the Jan. 23 announcement, but the gains were quickly sold. Geron's stock has fallen steadily since then, hitting a low of $3.79 on March 5, hurt in part by a $43 million spot financing deal and a sharp downturn in the broader market.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
STEM $0.89 0.00%
ASTM $3.59 -2.97%
CYTX $1.12 0.00%
GERN $4.14 0.00%
AAPL $127.60 0.00%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs